Thrombus can be a real problem for patients with PICCs. Biologically, a patient responds to a catheter insertion within 24 hours by developing bio-film, leading to thrombus that can cause catheter occlusion, infection, or dislodge into the bloodstream.
Maple Grove, MN (Vocus) August 26, 2009
r4 Vascular announces the commercial availability of the new Zeus™ Coated CT Peripherally-inserted Central Catheter (PICC). A novel coating on the catheter surface mimics the glycocalyx layer found on natural endothelial tissue surfaces in vessel walls. Laboratory tests prove that mimicking the glycocalyx layer can dramatically reduce thrombus formation on the internal and external surface of the catheter.
According to Gail Sansivero, MS, ANP, Vascular and Interventional Radiology Nurse Practitioner, Albany Medical Center, "Thrombus can be a real problem for patients with PICCs. Biologically, a patient responds to a catheter insertion within 24 hours by developing bio-film, leading to thrombus that can cause catheter occlusion, infection, or dislodge into the bloodstream."
Developing the catheter, r4 Vascular engineers took a cue from stealth coating technologies, approaching the thrombus problem by camouflaging the catheter in a biomimetic coating. Laboratory testing has shown the coating to be so effective that the Zeus™ Coated CT Catheter is the first non-valved PICC to receive FDA clearance for saline-only maintenance.
The Zeus™ Coated CT PICC is one of several keynote technologically-advanced catheter systems from r4 Vascular. r4 Vascular marks its entry into the vascular access marketplace with the Zeus™ Coated CT PICC, and the Pegasus™ Uncoated CT PICC. The two catheters will debut at the 23rd Annual Scientific Meeting of the Association for Vascular Access, being held September 15-17, 2009 in Las Vegas, NV. A new drainage catheter designed for easier placement and exchange is also now available from r4 Vascular.
According to r4 Vascular President, Donald Geer, "r4 Vascular's commitment is to save hospitals money and improve patient care, consequently we launched the Zeus Coated CT PICC to reduce thrombus complications and their related expenses; but we also recognize that not all patients will be exposed to the complications that our biomimetic coating was designed to reduce, so we launched our uncoated Pegasus PICC for patients that may not require a coated catheter."
r4 Vascular is a privately-held vascular access company driving innovation in vascular access medical technology. r4's passion is "uncomplicating" venous access, chemotherapy, and drug delivery, through product improvements that help catheters remain patent and effective, with reduced risk of complications.
# # #